common bleeding disorders in cancer patients€¦ · • bleeding is common in cancer, due to...
TRANSCRIPT
![Page 1: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/1.jpg)
Common Bleeding Disorders in Cancer Patients
(June 29, 2018) Thein Hlaing Oo, MD, FRCPE, FACP
Professor of Medicine / Consultant Hematologist The University of Texas M. D. Anderson Cancer Center, Houston, USA
![Page 2: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/2.jpg)
Faculty Disclosure
Company Name Honoraria/ Expenses
Consulting/ Advisory Board
Funded Research
Royalties/ Patent
Stock Options
Ownership/ Equity
Position Employee Other
(please specify)
Diichi-Sankyo x
Janssen Pharmaceuticals x Medical Education Speakers Network x
No, nothing to disclose X Yes, please specify:
![Page 3: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/3.jpg)
• The Scope of the problem of cancer and bleeding • Common Causes of Bleeding in Cancer • Management of Bleeding in Cancer Patients
![Page 4: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/4.jpg)
Cancer and Bleeding: The Scope of the Problem
![Page 5: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/5.jpg)
Cancer Associated Bleeding
• Gastrointestinal Bleeding > 300,000 hospitalizations (1 - 2% of all US hospitalizations)
Upper : 50-100/100,000 persons per year Lower : 30 – 36/100,000 persons per year 10% cancer (cancer per se or therapy-related)
• Hemoptysis
100/100,000 persons per year Cancer discovered in 8% in men and 4.3% in women
• Hematuria
Cancer discovered in 8% in men and 3.7% in women • Postmenopausal Bleeding
5% of all gynecological consultations 7 -10% found to have cancer
El-Tawil et al. World J Gastroenterol 2012;18:1154; Ghassemi et al. Curr Gastroenterol Rep 2013;15:333; Chung P et al. Acute Gastrointestinal Bleeding – Diagnosis & Treatment; p3-7; Jones et al. BMJ 2009;339; Yafi et al. Can Urology Assoc J 2011;5:97; Grossfeld. Urology 2001;57:604; Johnson. J Urol 2008;72:498
![Page 6: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/6.jpg)
• Atrial Fibrillation Prevalence: 2.7 – 6.1 millions
• Coronary Heart Disease Prevalance: 15 millions ( ≥ 20 years old)
• Venous Thromboembolism Annual incidence: 104 – 183 /100,000 person-years 20% of all VTE due to cancer
• CKD stage 3 (eGFR 30 – 59) Prevalence 6% of general population
• Bleeding rates (6-12 months):
Major: 2.4 – 10.2% Clinically Relevant Nonmajor Bleeding: 15 – 20%
Anticoagulant – associated Bleeding
www.cdc.gov, accseeed 6/24/2018; Westendorf: Blood 2014;124:955-962; Eikelboom. Am J Med 2016;129:533; Lee AY: N Engl J Med 2003;349:146; Lee AY. JAMA 2015;314:677; Raskob GE. N Engl J Med 2018;378:615; Young AM. J Clin Oncol 2018 [Epub]; Writing Group Members. Circulation 2016;133:447; Heit JA. Nat Rev Cardiol 2015;12:464-474 ; Ross JA. Thromb Res 2017:150:86; Francis CW, J Thromb Haemost 2015;13:1028
![Page 7: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/7.jpg)
Major Bleeding • Fatal bleeding • Bleeding in a critical area or organ; intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, intramuscular with compartment syndrome • Fall in Hb ≥ 2g/dL or leading to transfusion of ≥ 2 units whole blood or packed RBCs Clinically Relevant Nonmajor Bleeding • Any signs or symptoms of hemorrhage that does not fit the criteria for major bleeding • a face-to-face evaluation • and/or hospitalization or increased level of care • And/or requires medical intervention
Major Bleeding vs Clinically Relevant Nonmajor Bleeding
Schulman et al. J Thromb Haemost 2005;3:692-694 Kaatz et al. J Thromb Haemost 2015;13:2119-26
![Page 8: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/8.jpg)
Major Bleeding & CRNMB rates in Cancer VTE Trials
Trials Major Bleeding (%) CRNMB (%) CLOT NEJM 2003 6 months
Dalteparin VKA Dalteparin VKA
4 6 10 13 CATCH JAMA 2015 6 months
Tinzaparin VKA Tinzaparin VKA
2.7 2.4 10.9 15.3
DALTECAN J Thromb Haemost 2015 (12 months)
Dalteparin
10.2
Houkusai Cancer VTE NEJM 2018 (12 months)
Dalteparin Edoxaban Dalteparin Edoxaban
4
6.9 11.1 14.6
SELECT-D J Clin Oncol 2018 (6 months)
Dalteparin Rivaroxaban Dalteparin Rivaroxaban
4 6 4 13
![Page 9: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/9.jpg)
Common Causes of Bleeding in Cancer
Patients
University of Texas M.D. Anderson Cancer Center Experience
![Page 10: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/10.jpg)
Vascular Bleeding (Tumor erosion & others) • Hematochezia, Melena Hemetemesis • Epistaxis • Hemoptysis
• Intracranial hemorrhage • Hematuria/GU bleeding
Gastroenterology
ENT
Pulmonary
Neurosurgery
Urology Gynecology
![Page 11: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/11.jpg)
Bleeding Consults at M.D. Anderson Cancer Center
CRNM bleeding
![Page 12: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/12.jpg)
Bleeding Consults to Hematology
0
10
20
30
40
50
60
%
![Page 13: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/13.jpg)
Location of Bleeding
0
5
10
15
20
25
30
%
![Page 14: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/14.jpg)
Management of Bleeding in Cancer
Patients
![Page 15: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/15.jpg)
Management • Assessment & treatment sometimes occur simultaneously
• Arrest bleeding • Venous Access
• Stop all anticoagulants and antiplatelet drugs • Volume replacement • Stat Labs : CBC, review smear, PT, PTT, fibrinogen, D-dimers, chemistry,
type & crossmatch, urgent coag studies (if needed)
• Interventions
![Page 16: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/16.jpg)
Vascular Bleeding (Tumor erosion & others) • Hematochezia, Melena Hemetemesis • Epistaxis • Hemoptysis
• Intracranial hemorrhage • Hematuria/GU bleeding
Gastroenterology
ENT
Pulmonary
Neurosurgery
Urology Gynecology
General Measures
• Nonadherent dressings • Hemostatic dressings • Hemostastic agents • Radiotherapy • Surgery • Endoscopy • Interventional radiology
• Adjunctive therapy
Adapted from Pereira J et al. The Oncologist, 2004:9:561-570
![Page 17: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/17.jpg)
Medical Bleeding
• Platelet Defect - Quantitative (Thrombocytopenia) - Qualitative (NSAIDs, M-protein)
• Coagulation Factor Defect
- Deficiency - Inhibitors (esp. anticoagulants)
• Fibrinolysis Defect - Hyperfibrinolysis
![Page 18: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/18.jpg)
I. Anticoagulant-associated Bleeding
![Page 19: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/19.jpg)
LMWHX-ainhibitors
VKA
Dabigatran
UFH
MD Anderson Experience: Anticoagulant – Associated Bleeding
![Page 20: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/20.jpg)
Anticoagulation Indications
![Page 21: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/21.jpg)
Onset of Bleeding Complications in VTE patients
0
10
20
30
40
50
60
1mth 2-3mth 4-6mth 7-12mth 13-24mth >24mth
%
![Page 22: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/22.jpg)
Management of Anticoagulant-Associated Bleeding
• General & local measures and stop anticoagulants
Unfractionated Heparin (UFH) • UFH ½ life = 60- 90 minutes • 1mg of protamine neutralizes 100 IU of UFH
Time elapsed since heparin dose Dose of protamine (mg) to neutralize 100 IU of UFH
Immediate 1.0 – 1.5 mg/100 IU of UFH 30 – 60 min 0.5 – 0.75 mg/100 IU of UFH > 2 hrs 0.25 – 0.375 mg/100 IU of UFH
• Not ≥ 50 mg of protamine • Monitor APTT • Second dose may be necessary
https://reference.medscape.com/drug/protamine-343746, accessed June 3, 2018
![Page 23: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/23.jpg)
Low-molecular weight heparins (LMWH) • LMWH ½ life = 4-7 hours • Protamine neutralizes 60 % of anti-Xa activity
Management of Anticoagulant-Associated Bleeding
https://reference.medscape.com/drug/protamine-343746, accessed June 3, 2018; clincalc.com/Protamine/, accessed June 3, 2018
LMWH Time elapsed since LMWH dose
Protamine dose (mg)
Enoxaparin < 8 hrs 8 – 12 hrs
1mg/ 1mg enoxaparin 0.5 mg/1 mg enoxaparin
Dalteparin Tinzaparin
< 8 hrs 8 -12 hrs
1mg/ 100 anti-Xa units 0.5 mg/100 anti-Xa units
• Not ≥ 50 mg of protamine per dose • Second dose may be necessary
![Page 24: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/24.jpg)
Vitamin K Antagonists (VKA) • Warfarin ½ life: 20-60 hours • IV Vitamin K 5-10 mg • 4F- Prothrombin Complex Concentrate (PCC)
- INR 2 - 4: 25 IU/kg - INR 4 - 6: 35 IU/kg - INR > 6 : 50 U/kg
• If 4F-PCC not available, fresh frozen plasma 10-15 ml/kg
Management of Anticoagulant-Associated Bleeding
Adapted from Tomaselli et al. J Am Coll Cardiol 2017;70:3042-3067
![Page 25: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/25.jpg)
Figure 1. Management of direct oral anticoagulant-associated bleeding.
Weitz JI, Jaffer IH and Fredenburgh JC. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants [version 1]. F1000Research 2017, 6:985 (doi: 10.12688/f1000research.11174.1)
Andexanet alfa
![Page 26: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/26.jpg)
II. Thrombocytopenia
![Page 27: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/27.jpg)
Mechanisms of Thrombocytopenia
o Decreased bone marrow production of platelets marrow failure : aplastic anemia, myelodysplasia marrow infiltration : leukemias, myeloma, myelofibrosis myelosuppression : cytotoxic drugs and radiotherapy o Increased peripheral destruction of platelets immune thrombocytopenic purpura ( ITP ) o Consumption thrombocytopenia heparin-induced thrombocytopenia, DIC, TTP/HUS, HELLP o Platelet sequestration hypersplenism
![Page 28: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/28.jpg)
Gaydos LA et al. N Engl J Med 1962;266:905-909.
Relation between Hemorrhage and Platelet Count (92 patients with acute leukemia)
Category PLT count/cmm
A B C D E F G H
< 1,000 1,000 – 3,000 3,000 – 5,000 5,000 – 10,000 10,000 – 20,000 20,000 – 50,000 50,000 – 100,000
> 100,000
Curve I Curve 2 Curve 3
All hemorrhage Skin hemorrhage & epistaxis excluded Grossly visible hemorrhage
![Page 29: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/29.jpg)
Platelet Transfusion Guidelines (ASCO)
Schiffer CA et al. J Clin Oncol 2017;36:283-301
Conditions Platelet K/cmm
Comment
Hematologic malignancies < 10 Transfuse at higher count – bleeding, fevers, hyperleukocytosis, clotting abnormalities, invasive procedures
Stem cell transplantation < 10 Transfuse at higher levels based on judgement
Chronic, stable, severe thrombocytopenia (not on therapy, e.g. MDS, Aplastic anemia)
Consider observation; reserve transfusion for episodes of bleeding or during therapy
Solid tumors < 10 Transfuse at higher levels if bleeding
Invasive procedures 40-50K for major procedures ≥ 20K for bone marrow biopsy, central line, etc
![Page 30: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/30.jpg)
III. Disseminated Intravascular Coagulation
![Page 31: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/31.jpg)
Disseminated Intravascular Coagulation
o Pathophsiolgy (1) extensive endothelial injury (2) release of thromboplastin-like substances and activation of coagulation cascade (3) activation of fibrinolysis o Causes:
tissue damage ( eg. trauma ) complications of pregnancy ( release of tissue factor) neoplasia ( tissue factor, protease, TNF, etc ) infection vascular disorders immunological (complement activation, tissue factor)
![Page 32: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/32.jpg)
Pathophysiology of DIC Clotting system activation XIIa Plasmin
thrombin
Fibrinogen Fibrinopeptide A&B
Fibrin monomer
Fibrin thrombi
Fibrin multimer
XIIIa
XIIIa
+
E
D
D
E D D +
Consumption thrombocytopenia
Platelet dysfunction
Consumption of Clotting factors
BLEEDING
THROMB- OSIS
Kinin generation
![Page 33: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/33.jpg)
Adapted from Thachil et al. J Thromb Haemost 2015;13:671-675
Cancer-associated DIC Procoagulant Hyperfibrinolytic Subclinical
Predominant type of cancer
Pancreatic cancer, adenocarcinoma
Acute promyelocytic leukemia (APL), metastatic prostate Ca
Many solid cancers
Predominant clinical symptom
thrombosis bleeding neither
Different clinical presentations
Features of arterial ischemia DVT, PE Marantic endocarditis
Bruising, mucosal and internal bleeding, trauma sites bleeding. Hemorrhage – most common cause of induction mortality in APL
Only laboratory abnormalities ( ↓ PLT, ↓ fibrinogen, ↑ PT/APTT, microangiopathic hemolytic anemia) May remain long-standing; worsen or improve depending on cancer
Treatment Treat underlying cancer Anticoagulation with heparin
Treat underlying cancer Supportive care with blood products
Treat underlying cancer ? Anticoagulation with heparin
![Page 34: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/34.jpg)
Management of Acute (Hyperfibrinolytic) DIC o Supportive therapy as required ( e.g. volume replacement ) o Replacement therapy - platelet transfusion
< 50 (if bleeding ) or < 30 in APL or < 20 in other cancers (at high risk of bleeding)
- cryoprecipitate/fibrinogen concentrate to replace fibrinogen - FFP to replace other factors o Monitor response with CBC, PTT, PT, fibrinogen o Specific therapy : eg. All trans-retinoic acid in APL
Levi M et al. Br J Haematol 2009;145:24-33; Thachill et al. J Thromb Haemost 2015;13:671-5
![Page 35: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/35.jpg)
• Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy.
• Vascular bleeding due to cancer invasion or therapy-related complications is very common.
• Medical causes of clinically relevant bleeding in cancer
include the use of antithrombotics, thrombocytopenia, qualitative defect in platelets, coagulation defects and sometimes multifactorial etiologies.
• Management of bleeding requires quick evaluation, arresting bleeding, replacement/supportive therapy and specific management.
Conclusion
![Page 36: Common Bleeding Disorders in Cancer Patients€¦ · • Bleeding is common in cancer, due to cancer per se or due to antineoplastic therapy or antithrombotic therapy. • Vascular](https://reader033.vdocuments.net/reader033/viewer/2022042911/5f42aa702e82fa0799135580/html5/thumbnails/36.jpg)
Thank you for your attention !